Keywords: alnylam, enters, ph, tekmira, rnai, cancer, drug

Alnylam enters Ph I with Tekmira RNAi cancer drug

Article | 08 April 2009

Print This

USA-based Alnylam Pharmaceuticals has initiated a Phase I trial of ALN-VSP, an RNAi therapeutic developed by Canada-based firm Tekmira for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in